| Ramucirumab studied in …STUDIED_INderived137 of 137show fewer |
|---|
| → studied in | NCT04310007Phase 2 · active not recruiting Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer · 137 trials list this drug (37 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · 137 trials list this drug (37 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06448754Phase 2 · active not recruiting Volrustomig Priming Regimens Exploratory Phase II Platform Study · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04340882Phase 2 · active not recruiting Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade · 137 trials list this drug (37 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07821684Phase 3 · not yet recruiting A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer · 137 trials list this drug (37 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04921904Phase 1/Phase 2 · completed Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca · 137 trials list this drug (37 active) | — | — | Esophageal Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05365581Phase 1 · recruiting A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04069273Phase 2 · active not recruiting Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma · 137 trials list this drug (37 active) | — | — | Gastric Neoplasm,Adenocarcinoma,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06445972Phase 1/Phase 2 · recruiting Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · 137 trials list this drug (37 active) | — | — | Esophageal Neoplasm,Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205968Phase 2 · recruiting Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers · 137 trials list this drug (37 active) | — | — | Small Intestinal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03650764Phase 1/Phase 2 · completed Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · 137 trials list this drug (37 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06007937Phase 1/Phase 2 · active not recruiting A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04145349Phase 1/Phase 2 · completed CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor · 137 trials list this drug (37 active) | — | — | Desmoplastic Small Round Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05999994Phase 2 · recruiting A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer · 137 trials list this drug (37 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04999761Phase 1 · recruiting AB122 Platform Study · 137 trials list this drug (37 active) | — | — | Malignant Head and Neck Neoplasm,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03281369Phase 1/Phase 2 · terminated A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) · 137 trials list this drug (37 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05719558Phase 1 · recruiting A Study of ASP1002 in Adults for Treatment of Solid Tumors · 137 trials list this drug (37 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02711553Phase 2 · active not recruiting A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer · 137 trials list this drug (37 active) | — | — | Malignant Neoplasm,Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06996782Phase 1/Phase 2 · recruiting A Platform Study in Non-Small Cell Lung Cancer (NSCLC) · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03081143Phase 2/Phase 3 · completed Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy · 137 trials list this drug (37 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098338Phase 2 · recruiting A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03872947Phase 1 · active not recruiting A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors · 137 trials list this drug (37 active) | — | — | Solid Neoplasm,Melanoma,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06038578Phase 2 · recruiting A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04332367Phase 2 · recruiting Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05062980Phase 1 · terminated Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05642572Phase 2 · recruiting Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) · 137 trials list this drug (37 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04704934Phase 3 · active not recruiting Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03527108Phase 2 · active not recruiting Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05096663Phase 2/Phase 3 · active not recruiting Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) · 137 trials list this drug (37 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594548Phase 1 · not yet recruiting Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma · 137 trials list this drug (37 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06251973Phase 2 · active not recruiting A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer · 137 trials list this drug (37 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm,Esophageal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06031688Phase 2 · recruiting Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) · 137 trials list this drug (37 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06616584Phase 2/Phase 3 · recruiting Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) · 137 trials list this drug (37 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03909334Phase 2 · active not recruiting Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · 137 trials list this drug (37 active) | — | — | Malignant Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633602Phase 3 · active not recruiting Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study · 137 trials list this drug (37 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03798626Phase 1 · completed Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers · 137 trials list this drug (37 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05980000Phase 2 · active not recruiting Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma · 137 trials list this drug (37 active) | — | — | Malignant Head and Neck Neoplasm,Head and Neck Carcinoma,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03686488Phase 2 · completed TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06771622Phase 1/Phase 2 · active not recruiting Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors · 137 trials list this drug (37 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03008278Phase 1/Phase 2 · completed Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery · 137 trials list this drug (37 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm,Esophageal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02411448Phase 3 · active not recruiting A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05980416Phase 1 · terminated Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 · 137 trials list this drug (37 active) | — | — | Neoplasm,Neoplasm by Site,Digestive System Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06675136Phase 1 · recruiting Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03694002Phase 2 · completed Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery · 137 trials list this drug (37 active) | — | — | Thymus Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02597036Phase 1 · terminated A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors · 137 trials list this drug (37 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05071053Phase 2 · terminated Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer · 137 trials list this drug (37 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05002127Phase 2/Phase 3 · active not recruiting A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04120454Phase 2 · completed Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer · 137 trials list this drug (37 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02678182Phase 2 · active not recruiting Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04394624Phase 2 · terminated Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) · 137 trials list this drug (37 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03560973Phase 2 · completed A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM · 137 trials list this drug (37 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02795858Phase 2 · completed A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors · 137 trials list this drug (37 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04499924Phase 2/Phase 3 · completed Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer · 137 trials list this drug (37 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02065765approved for marketing International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02307812approved for marketing Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02581215Phase 2 · completed Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer · 137 trials list this drug (37 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02791334Phase 1 · completed A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors · 137 trials list this drug (37 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Cutaneous Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03971474Phase 2 · completed Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) · 137 trials list this drug (37 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06564298Phase 2 · unknown A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis · 137 trials list this drug (37 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03520946Phase 3 · completed RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients · 137 trials list this drug (37 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06542731Phase 1 · active not recruiting An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02443324Phase 1 · completed A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer · 137 trials list this drug (37 active) | — | — | Transitional Cell Carcinoma,Lung Non-Small Cell Carcinoma,Malignant Biliary Tract Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03689855Phase 2 · completed Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03760822Phase 2 · unknown Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients · 137 trials list this drug (37 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03502746Phase 2 · terminated Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma · 137 trials list this drug (37 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05856864Phase 1 · unknown Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy · 137 trials list this drug (37 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04660760Phase 2 · recruiting Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02789345Phase 1 · completed A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04151563Phase 1/Phase 2 · withdrawn A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy · 137 trials list this drug (37 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04145700Phase 1/Phase 2 · terminated CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma · 137 trials list this drug (37 active) | — | — | Synovial Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02426125Phase 3 · completed A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer · 137 trials list this drug (37 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01079780Phase 2 · completed Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy · 137 trials list this drug (37 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520141Phase 2 · completed Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery · 137 trials list this drug (37 active) | — | — | Liver Carcinoma,Intrahepatic Cholangiocarcinoma,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05800418Phase 1 · completed Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04557384Phase 1 · terminated A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer · 137 trials list this drug (37 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03995017Phase 1/Phase 2 · unknown Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02435433Phase 3 · completed A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein · 137 trials list this drug (37 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03762564Phase 2 · completed Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy · 137 trials list this drug (37 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02661971Phase 2/Phase 3 · completed FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) · 137 trials list this drug (37 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02317991Phase 2 · completed Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer · 137 trials list this drug (37 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02898077Phase 3 · completed A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03904108Phase 2 · terminated Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04040361Phase 2 · unknown Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01515306Phase 2 · completed A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors · 137 trials list this drug (37 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02970539Phase 1 · unknown Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers · 137 trials list this drug (37 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00703326Phase 3 · completed Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer · 137 trials list this drug (37 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007769Phase 2 · withdrawn Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC · 137 trials list this drug (37 active) | — | — | Non-Small Cell Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02934464Phase 3 · unknown Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers · 137 trials list this drug (37 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314117Phase 3 · completed A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02564198Phase 1 · completed A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors · 137 trials list this drug (37 active) | — | — | Neoplasm,Central Nervous System Neoplasm,Childhood Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213289Phase 2 · completed PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression · 137 trials list this drug (37 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02572687Phase 1 · completed A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm,Hepatocellular Carcinoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01246986Phase 2 · completed A Study of LY2157299 in Participants With Hepatocellular Carcinoma · 137 trials list this drug (37 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02082210Phase 1/Phase 2 · completed A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer · 137 trials list this drug (37 active) | — | — | Malignant Neoplasm,Hepatocellular Carcinoma,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267913Phase 2 · withdrawn Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) · 137 trials list this drug (37 active) | — | — | Lung Carcinoma,Malignant Lung Neoplasm,Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02730247Phase 2 · completed Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02079636Phase 1 · completed A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02443883Phase 2 · completed A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02514551Phase 2 · completed A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02831491Phase 2 · withdrawn A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03704077Phase 2 · withdrawn An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03739801Phase 1/Phase 2 · withdrawn MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02726399Phase 2 · terminated Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer · 137 trials list this drug (37 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01703091Phase 2 · completed A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer · 137 trials list this drug (37 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01983878Phase 2 · completed A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00721162Phase 2 · completed Study of Ramucirumab in Ovarian Cancer · 137 trials list this drug (37 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00917384Phase 3 · completed Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma · 137 trials list this drug (37 active) | — | — | Adenocarcinoma,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01168973Phase 3 · completed A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01183780Phase 3 · completed A Study in Second Line Metastatic Colorectal Cancer · 137 trials list this drug (37 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03766607Phase 2 · withdrawn Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer · 137 trials list this drug (37 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01160744Phase 2 · completed A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02999295Phase 1/Phase 2 · completed A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer · 137 trials list this drug (37 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01111604Phase 2 · completed A Study of Ramucirumab or Icrucumab in Colorectal Cancer · 137 trials list this drug (37 active) | — | — | Malignant Colon Neoplasm,Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03966118Phase 2 · unknown Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma · 137 trials list this drug (37 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02745769Phase 1 · completed A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents · 137 trials list this drug (37 active) | — | — | Malignant Neoplasm,Malignant Colorectal Neoplasm,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01634555Phase 2 · completed A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI · 137 trials list this drug (37 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02069041Phase 1 · completed A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer · 137 trials list this drug (37 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01285037Phase 1 · completed A Study of LY2801653 in Advanced Cancer · 137 trials list this drug (37 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02359058Phase 1 · completed A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer · 137 trials list this drug (37 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00895180Phase 2 · completed Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme · 137 trials list this drug (37 active) | — | — | Adult Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01427933Phase 2 · completed A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer · 137 trials list this drug (37 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01682135Phase 1 · completed A Study in Participants With Advanced Solid Tumors · 137 trials list this drug (37 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01017731Phase 2 · completed Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes · 137 trials list this drug (37 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00735696Phase 2 · completed A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer · 137 trials list this drug (37 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00683475Phase 2 · completed A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer · 137 trials list this drug (37 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01567163Phase 2 · completed A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors · 137 trials list this drug (37 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00627042Phase 2 · completed Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy · 137 trials list this drug (37 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01246960Phase 2 · completed A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer · 137 trials list this drug (37 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01286818Phase 1 · completed A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) · 137 trials list this drug (37 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00533702Phase 2 · completed A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma · 137 trials list this drug (37 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00515697Phase 2 · completed A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma · 137 trials list this drug (37 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01005355Phase 1 · completed Study of IMC-1121B in Patients With Advanced Solid Tumors · 137 trials list this drug (37 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01253525Phase 1 · completed Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas · 137 trials list this drug (37 active) | — | — | Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01256567Phase 1 · completed A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer · 137 trials list this drug (37 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00862784Phase 2 · completed A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer · 137 trials list this drug (37 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00786383Phase 1 · completed Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy · 137 trials list this drug (37 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00793975Phase 1 · completed Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy · 137 trials list this drug (37 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |